Sandbox Reserved 1227
From Proteopedia
(Difference between revisions)
Line 7: | Line 7: | ||
== Relevance == | == Relevance == | ||
- | Often, the p53 pathway is compromised due to the over expression of proteins such as MDM2 or MDM4. This over expression can lead to decreased activity of p53 which allows the cell to proliferate even when the body signals it to be destroyed. This is thought to be one of the lead causes of tumor progression<sup>[1]</sup>. Data involving MDM2 and the SNP285 polymorphism within its promotor region have been researched, and this region has been shown to be significantly linked to a decreased cancer risk<ref>Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.</ref>. It is believed that further MDM2 research and therapy could possibly lead to an anticancer strategy <ref>Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.</ref>. | + | Often, the p53 pathway is compromised due to the over expression of proteins such as MDM2 or MDM4. This over expression can lead to decreased activity of p53 which allows the cell to proliferate even when the body signals it to be destroyed. This is thought to be one of the lead causes of tumor progression<sup>[1]</sup>. Data involving MDM2 and the SNP285 polymorphism within its promotor region have been researched, and this region has been shown to be significantly linked to a decreased cancer risk<ref>Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.</ref>. It is believed that further MDM2 research and therapy could possibly lead to an anticancer strategy <ref>Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.</ref>. However, the cancer cells are very good at acquiring mutations to allow them to survive even in the presence of these drugs. Also, adverse side effects have been noted when trying to use these anti-cancer strategies<sup>[1]</sup>. |
== Structural highlights == | == Structural highlights == |
Revision as of 15:06, 25 April 2017
This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
MDM2
|
References
- ↑ Eischen, C. M., & Lozano, G. (2014). The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Human Mutation, 35(6), 728–737. http://doi.org/10.1002/humu.22524
- ↑ Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.
- ↑ Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.
- ↑ Ciemny, M. P., Debinski, A., Paczkowska, M., Kolinski, A., Kurcinski, M., & Kmiecik, S. (2016). Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction. Scientific Reports, 6, 37532. http://doi.org/10.1038/srep37532.